These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Osteomalacia and osteitis fibrosa in a man ingesting aluminum hydroxide antacid. Carmichael KA, Fallon MD, Dalinka M, Kaplan FS, Axel L, Haddad JG. Am J Med; 1984 Jun; 76(6):1137-43. PubMed ID: 6328994 [Abstract] [Full Text] [Related]
4. Bone aluminum and histomorphometric features of renal osteodystrophy. Hodsman AB, Sherrard DJ, Alfrey AC, Ott S, Brickman AS, Miller NL, Maloney NA, Coburn JW. J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841 [Abstract] [Full Text] [Related]
5. Elevated bone aluminum content in dialysis patients without osteomalacia. McCarthy JT, Kurtz SB, McCall JT. Mayo Clin Proc; 1985 May; 60(5):315-20. PubMed ID: 3990380 [Abstract] [Full Text] [Related]
20. Use of bone mineral content determination in the evaluation of osteodystrophy among hemodialysis patients. Heaf JG, Nielsen LP, Mogensen NB. Nephron; 1983 Mar; 35(2):103-7. PubMed ID: 6621754 [Abstract] [Full Text] [Related] Page: [Next] [New Search]